Clinical trials: Mild Cognitive Impairment
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
This trial will determine the pharmacokinetics of Posiphen® in both plasma and CSF after a 10-day treatment period with Posiphen® in subjects with amnestic MCI.
- Trial name
- NCT01072812
- Testing
- Posiphen® tartrate capsules
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Annovis Bio Inc.
Mild Cognitive Impairment (MCI), Alzheimer Disease
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases
- Trial name
- NCT05321498
- Testing
- XPro1595
- Sponsor
- Inmune Bio, Inc.
Alzheimer's Disease
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
1. To evaluate the diagnostic performance of [18F]-APN-1607 injection PET imaging in detecting uptake patterns consistent with AD neuropathological changes as defined by the National Institute on Aging-Alzheimer's Association…
- Trial name
- NCT07752784
- Testing
- [18F]-APN-1607
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Mild Cognitive Impairment, Alzheimer's Disease
Comparison of PET Amyloid Imaging in Japanese and Western Subjects
This was a Phase 2, multicenter study to assess the extent and patterns of [18F] flutemetamol uptake in the brains of 3 groups of Japanese subjects: healthy volunteers (HV), amnestic mild cognitive impairment (aMCI), and probable…
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Healthy
- Trial name
- NCT02813070
- Testing
- [18F] Flutemetamol
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Healthy, Alzheimer Disease
A Study to Measure CSF Proteins in Elderly Healthy Volunteers and Volunteers With Mild Cognitive Impairment or Alzheimer's Disease
The purpose of this study is to investigate changes of cerebral spinal fluid (CSF) proteins over time using continuous CSF sampling for 36 hours in elderly healthy volunteers and volunteers with mild cognitive impairment or…
- Trial name
- NCT01436188
- Testing
- Standard CSR sampling procedure, Alternate frequency CSR sampling procedure, Standard frequent CSR sampling procedure with 800 mg ibuprofen
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease (AD)
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.
- Trial name
- NCT06114745
- Testing
- SHR-1707 injection
- Where
- 3 sites in Australia
- Volunteers
- 2 people
- Sponsor
- Atridia Pty Ltd.
Multiple Sclerosis, Mild Cognitive Impairment
Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms
CT-100 is a platform that provides an interactive, software based therapeutic component that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital…
- Conditions
- Multiple Sclerosis, Mild Cognitive Impairment, Cancer
- Trial name
- NCT05438147
- Testing
- CT-100 DiNaMo, Care-as-Usual
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Click Therapeutics, Inc.
Mild Cognitive Impairment
Effect of Consuming a Mixture of Extracts and DHA on the Mild Cognitive Impairment
The objective of this trial is to evaluate the effect of the consumption of a mixture of extracts and DHA on the mild cognitive impairment.
- Trial name
- NCT06254040
- Testing
- mixture of extracts and DHA
- Where
- Spain
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Alzheimer Disease, Dementia
Reducing Dementia Risk With Digital Health Coaching
The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- DC-MARVEL (NCT04559789)
- Testing
- MindMate + Health Coaching, Health Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neurotrack Technologies, Inc.
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimers Disease
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or…
- Trial name
- ADELAIDE (NCT06856681)
- Testing
- PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing
- Sponsor
- C2N Diagnostics
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Alzheimer's Disease
Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)
Subjects will be adults aged 50 to 85 years who have subjective memory complaints and mild cognitive impairment or mild dementia due to Alzheimer's disease (AD).
- Trial name
- NCT01600859
- Testing
- E2609
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eisai Inc.
Dementia, Mild Cognitive Impairment
Prospective Research in Memory Clinics (PRIME)
The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia.
- Trial name
- NCT00297271
- Testing
- Current treatment practice of each participating physician
- Where
- 9 sites in Australia
- Volunteers
- 970 people
- Sponsor
- Janssen-Cilag Pty Ltd
Mild Cognitive Impairment, Mild Dementia
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04148391
- Testing
- NYX-458
- Where
- 26 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aptinyx
Healthy, Alzheimer's Disease
A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY2599666 in different groups of people - those who are healthy, those who have mild cognitive impairment due to Alzheimer's…
- Conditions
- Healthy, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- NCT02614131
- Testing
- LY2599666, Solanezumab
- Where
- 5 sites in United States, Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dementia, Mild, Cognitive Disorder Mild
The Pilot Study of Medical Device-Neuclare for Patients With Mild Cognitive Disorder and Early Dementia
This clinical trial aims to explore the effectiveness and safety of cognitive function improvement of Neuclare, a science medical device, for patients with mild cognitive impairment and early Alzheimer's disease.
- Trial name
- NCT05633095
- Testing
- Neuclare
- Where
- 2 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Deepsonbio
Alzheimer Disease
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
This is a Phase Ia/Ib, two-part, randomized, placebo-controlled, double-blinded, first in human(FIH) study to evaluate the safety, tolerability, PK, and PD of ADEL-Y01 in healthy participants in Part 1 and participants with MCI…
- Trial name
- NCT06247345
- Testing
- ADEL-Y01 - healty participants, ADEL-Y01 - MCI/AD
- Where
- 6 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Expert Lab (ADEL), Inc.
Alzheimer's Disease
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
- Trial name
- NCT01548430
- Testing
- TTP4000
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- vTv Therapeutics